Food News and Research

RSS

Researchers settle controversy over the mechanism by which silver nanoparticles kill bacteria

Rice University researchers have settled a long-standing controversy over the mechanism by which silver nanoparticles, the most widely used nanomaterial in the world, kill bacteria.

12 Jul 2012

Arena files lorcaserin hydrochloride MAA with Swissmedic

Arena Pharmaceuticals, Inc. announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland.

12 Jul 2012

New book outlines cutting-edge approach to systematically address AD

ADEC Inc. - Worried about your memory? Many patients with Alzheimer's disease (AD) and individuals concerned about developing memory loss feel they have limited options. While there is no 'magic pill' to cure or prevent AD, a new book outlines a cutting-edge approach to systematically address this disease.

12 Jul 2012

Novel molecular mechanism responsible for most important symptom of major depression

Stanford University School of Medicine scientists have laid bare a novel molecular mechanism responsible for the most important symptom of major depression: anhedonia, the loss of the ability to experience pleasure.

12 Jul 2012

BioControl Medical receives FDA approval to initiate second phase of CardioFit study for heart failure

BioControl Medical has announced U.S. Food and Drug Administration approval to begin the second phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company's CardioFit system for heart failure.

12 Jul 2012

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

Spinal Restoration, Inc. announced today the completion of enrollment in the Phase III Investigational New Drug (IND) study of the Biostat System. The Phase III clinical trial is a 260-subject, randomized, blinded, placebo controlled study designed to assess the ability of the Biostat System to reduce pain and improve function in patients with chronic discogenic low back pain.

12 Jul 2012

FDA approves Watson’s ANDA for generic ARTHROTEC

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc - Florida has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Diclofenac Sodium and Misoprostol Delayed-Release Tablets, the generic equivalent to G.D. Searle's ARTHROTEC.

12 Jul 2012

Viewpoints: Trouble keeping health costs down; Ignagni says law needs some revisions; Coverage is like clean water

Now that the Supreme Court has provided legal certainty on the recent healthcare reform law, the nation must turn its attention to affordability. While the law expands coverage to millions of Americans, a goal health plans have long supported, major provisions of the law need to be changed to avoid significant cost increases for consumers and employers.

12 Jul 2012

Saponins may increase lamb growth rates

Study results show that the growth rate of female lambs given feed drenched with Agave extract or Quillaja saponaria – both of which contain saponins – increased over 2 months, indicating they may act as natural defaunating agents.

11 Jul 2012

Arrowhead initiates Adipotide Phase 1 trial in obesity

Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.

11 Jul 2012

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bevacizumab in combination with chemotherapy, an established cancer treatment in this indication, and found no overall survival benefit when adding bevacizumab to chemotherapy.

11 Jul 2012

FDA clears Asthmapolis’ sensor system and associated software

Asthmapolis announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its asthma sensor system and associated software to healthcare providers and their patients.

11 Jul 2012

TLR1 plays a critical role in protecting the body from food-borne illnesses

A naturally occurring protein called TLR1 plays a critical role in protecting the body from illnesses caused by eating undercooked pork or drinking contaminated water, according to new research from the University of Southern California (USC).

11 Jul 2012

President Obama signs FDA bipartisan bill

President Obama signed into law the bipartisan Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) on July 9.

11 Jul 2012

Nutrient cocktail can boost memory in patients with mild cognitive impairment

A clinical trial of an Alzheimer's disease treatment developed at MIT has found that the nutrient cocktail can improve memory in patients with early Alzheimer's. The results confirm and expand the findings of an earlier trial of the nutritional supplement, which is designed to promote new connections between brain cells.

11 Jul 2012

Abused children may become obese adults

Severity of abuse in childhood or adolescence is associated with an increased risk for overall and central obesity in adulthood, report researchers.

10 Jul 2012

Caffeine combats skin cancer risk

Drinking three or more cups of caffeinated coffee a day can significantly reduce a person’s risk for basal cell carcinoma, show study findings.

10 Jul 2012

Salt content in UK takeaway meals ‘alarmingly high’

The level of salt in hot takeaway meals from small independent outlets in the UK should be reduced to minimize adverse health consequences, say researchers who found that levels were disturbingly high.

10 Jul 2012

FDA acknowledges receipt of resubmission of Human Genome Sciences’ raxibacumab BLA

Human Genome Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for raxibacumab, a treatment for inhalational anthrax, and has established December 15, 2012 as the Prescription Drug User Fee Act (PDUFA) action date.

10 Jul 2012

Nearly 3.8M California adults are food insecure: New policy brief

An estimated 3.8 million California adults - particularly those in households with children, as well as low-income Latinos - could not afford to put adequate food on the table during the recent recession, according to a new policy brief by the UCLA Center for Health Policy Research.

10 Jul 2012